Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

2019 ◽  
Author(s):  
Mueller-Godeffroy E ◽  
Vonthein R ◽  
Ludwig-Seibold C ◽  
Heidtmann B ◽  
Boettcher C ◽  
...  
Keyword(s):  
Insulin Pump ◽  
Controlled Trial ◽  
Diabetes Type ◽  
Insulin Pump Therapy ◽  
Diabetes Type 1 ◽  
Pump Therapy ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial ◽  
Psychosocial Benefits

Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial

2018 ◽  
Vol 19 (8) ◽  
pp. 1471-1480 ◽  
Author(s):  
Esther Mueller‐Godeffroy ◽  
Reinhard Vonthein ◽  
Carmen Ludwig‐Seibold ◽  
Bettina Heidtmann ◽  
Claudia Boettcher ◽  
...  
Keyword(s):  
Insulin Pump ◽  
Controlled Trial ◽  
Diabetes Type ◽  
Insulin Pump Therapy ◽  
Diabetes Type 1 ◽  
Pump Therapy ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial ◽  
Psychosocial Benefits

scholarly journals Underestimation of actual insulin needs among people with diabetes type 1 on insulin pump therapy

2016 ◽  
Vol 13 ◽  
pp. e62
Author(s):  
Parthena Giannoulaki ◽  
Iro Gounitsioti ◽  
Fotis Iliadis ◽  
Apostolos Hatzitolios ◽  
Aggelos Pappas ◽  
...  
Keyword(s):  
Insulin Pump ◽  
Diabetes Type ◽  
Insulin Pump Therapy ◽  
Diabetes Type 1 ◽  
Pump Therapy

scholarly journals A Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes

Diabetes Care ◽  
2005 ◽  
Vol 28 (6) ◽  
pp. 1277-1281 ◽  
Author(s):  
L. A. Fox ◽  
L. M. Buckloh ◽  
S. D. Smith ◽  
T. Wysocki ◽  
N. Mauras
Keyword(s):  
Randomized Controlled Trial ◽  
Type 1 Diabetes ◽  
Young Children ◽  
Insulin Pump ◽  
Controlled Trial ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Randomized Controlled

scholarly journals Bolus wizard use has a beneficial effect in glycemic control among people with diabetes type 1 on insulin pump therapy

2016 ◽  
Vol 13 ◽  
pp. e62-e63 ◽  
Author(s):  
Parthena Giannoulaki ◽  
Iro Gounitsioti ◽  
Fotios Iliadis ◽  
Apostolos Hatzitolios ◽  
Aggelos Pappas ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Beneficial Effect ◽  
Insulin Pump ◽  
Diabetes Type ◽  
Insulin Pump Therapy ◽  
Diabetes Type 1 ◽  
Pump Therapy

scholarly journals CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e045650
Author(s):  
Sidse Kjærhus Nørgaard ◽  
Elisabeth Reinhardt Mathiesen ◽  
Kirsten Nørgaard ◽  
Tine Dalsgaard Clausen ◽  
Peter Damm ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Pump ◽  
Controlled Trial ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Acting Insulin ◽  
Pregnancy And Lactation ◽  
Randomised Controlled

IntroductionFaster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and lactation and on fetal growth and infant health.Methods and analysisAn open-label randomised controlled trial of pregnant women with type 1 or type 2 diabetes including women on multiple daily injection (MDI) therapy or insulin pump therapy. During a 2-year inclusion period, approximately 220 women will be randomised 1:1 to Fiasp or NovoRapid in early pregnancy and followed until 3 months after delivery. At 9, 21 and 33 gestational weeks and during planned induction of labour or caesarean section, women are offered blinded continuous glucose monitoring (CGM) for 7 days. Randomisation will stratify for type of diabetes and insulin treatment modality (MDI or insulin pump therapy, respectively). Health status of the infants will be followed until 3 months of age. The primary outcome is birth weight SD score adjusted for gestational age and gender. Secondary outcomes include maternal glycaemic control including glycated haemoglobin, preprandial and postprandial self-monitored plasma glucose levels, episodes of mild and severe hypoglycaemia, maternal gestational weight gain and weight retention, CGM time spent in, above and below target ranges as well as pregnancy outcomes including pre-eclampsia, preterm delivery, perinatal mortality and neonatal morbidity. Data analysis will be performed according to the intention-to-treat principle.Ethics and disseminationThe trial has been approved by the Regional Ethics Committee (H-19029966) on 7 August 2019. Results will be sought disseminated in peer-reviewed journals and at scientific meetings.Trial registration numberNCT03770767

scholarly journals Stress Management in Parents of Children with Diabetes Type 1: A Randomized Controlled Trial

Psychology ◽  
2015 ◽  
Vol 06 (08) ◽  
pp. 1040-1050 ◽  
Author(s):  
Niki S. Pateraki ◽  
Evaggelia Mantzourani ◽  
Panagiota P. Darvyri ◽  
Evangelos C. Alexopoulos ◽  
Liza Varvogli ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Stress Management ◽  
Controlled Trial ◽  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document